Compare Modine Manufacturing Company (MOD) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Modine Manufacturing Company vs Smith & Nephew plc — how do they compare? Modine Manufacturing Company trades at $181.51 (market cap $9.66B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Modine Manufacturing Company and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays a 2.95% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals — on Pluang, investors hold Modine Manufacturing Company for 33 Days and Smith & Nephew plc for 121 Days on average.
| MOD | SNN | |
|---|---|---|
Market Cap | $9.66B | $11.10B |
Volume | 1,331,946 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $283.95 | $37.17 |
52-Week Low | $110.73 | $26.42 |
Typical Hold Time | 33 Days | 121 Days |
Enterprise Value | $10.09B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Modine Manufacturing (MOD) trades at $184.32, down 2.7% on the day, amid a recent spin-off of its Performance Technologies unit. The stock exhibits bearish technical signals with support at $177 and resistance at $187. Fundamentally, the company reported strong Q2 2026 earnings of $1.53 per share, beating estimates, but faces margin compression with net income margin declining from 7.12% in 2025 to 4.27% in 2026. Analyst sentiment remains positive with a consensus price target of $331.25 and 10 buy ratings.
The outlook for MOD is mixed; the spin-off could streamline operations and focus on thermal management growth, but integration risks and margin pressures pose challenges. The stock trades at a high P/E of 67.87, suggesting premium valuation. Upside depends on execution of the new corporate strategy and data center cooling expansion, while downside risks include competitive pressures and macroeconomic headwinds affecting industrial demand.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
